Bridgewater, NJ 08807 USA
Research Sector Biotech Specialty Pharma
Summary Description Developing therapeutic manipulation technologies to treat Alzheimer's.Management Nikolaos Tezapsidis, PhD, President & CEO; Mark A. Smith, PhD, CSO; Jane M. Johnston, PhD, Executive Director of Research and Development; Eugene J. Oliva, MBA, Chief Financial Officer; Michael J. Hoy, M.S., Director of Regulatory Affairs.
Click here for Financial Data
Keywords: biochemistry, molecular, biology, biopharmaceuticals, protein, clinical development, Alzheimer's disease.
Updated: Oct. 03, 2014
Neurotez Inc. is a privately held Delaware corporation formed to launch the clinical development of recombinant human Leptin as a hormone replacement therapy for Alzheimer's disease ("AD"), and as a p......view more
Products / Services
The most advanced product is a recombinant Leptin product for Alzheimer's diseaase.......view more
Market / Customers
Alzheimer's Disease (AD) is the primary cause of cognitive impairment among the elderly (40-50% of 85 yr olds may have AD). There are currently 5.1 million people with AD in the US alone, costing over......view more
Competitors / Substitutes / Alternatives
Currently available AD drugs provide only limited symptomatic relief without addressing the underlying pathobiology of the disease. Drug development programs seeking to address AD are underway at a s...view more